Genitourinary Drugs Market Report 2026

The genitourinary drugs market size has grown steadily in recent years. It will grow from $31.02 billion in 2025 to $31.99 billion in 2026 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to urinary tract infection prevalence, aging population, hormonal disorder incidence, hospital pharmacy expansion, prescription drug adoption.

The genitourinary drugs market size is expected to see steady growth in the next few years. It will grow to $35.69 billion in 2030 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to personalized urology treatments, digital health platforms, reproductive health awareness, minimally invasive therapies, specialty clinic growth. Major trends in the forecast period include rising demand for uti and bph treatments, growing use of hormonal and fertility therapies, expansion of oral and topical drug forms, increased focus on women’s and men’s urological health, growth of online pharmacy distribution.

The increasing prevalence of genitourinary disorders is anticipated to drive the expansion of the genitourinary drugs market in the coming years. Genitourinary disorders are medical conditions affecting the genitourinary system, which includes both urinary and reproductive organs, such as infections, cancers, and functional or structural abnormalities. This rise in prevalence is largely attributed to the aging population, as age-related changes elevate the risk of urinary and reproductive health issues. Genitourinary drugs aid in managing these disorders by addressing urinary and reproductive system conditions, providing relief from infections, inflammation, and dysfunction. They enhance patient outcomes by delivering effective, convenient, and condition-specific treatments, ultimately improving overall quality of life. For example, according to an April 2024 report by the American Cancer Society, approximately 20 million new cancer cases were diagnosed worldwide in 2022, resulting in 9.7 million deaths, with projections indicating that cases could reach 35 million by 2050. Consequently, the rising prevalence of genitourinary disorders is fueling growth in the genitourinary drugs market.

Leading companies in the genitourinary drugs market are prioritizing the development of innovative products, such as oral antibiotics, to improve treatment convenience, enhance patient adherence, and effectively combat infections. Oral antibiotics are antibacterial medications administered orally to treat bacterial infections. For instance, in March 2025, GSK plc, a UK-based pharmaceutical firm, received approval from the US Food and Drug Administration (FDA) for Blujepa (gepotidacin) to treat uncomplicated urinary tract infections in women and girls aged 12 and above caused by susceptible bacteria. This first-in-class oral antibiotic works by inhibiting bacterial DNA replication, targeting two essential enzymes, DNA gyrase and topoisomerase IV. Unlike traditional antibiotics, it binds to unique sites to overcome resistance, offering a targeted mechanism with improved safety and efficacy.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition aims to transform cancer treatment by combining antibody-drug conjugate (ADC) technology with Pfizer’s global reach and expertise. Seagen Inc., a US-based biotechnology firm, specializes in innovative genitourinary cancer therapies, notably Padcev for advanced bladder cancer.

Major companies operating in the genitourinary drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Société Anonyme, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Zydus Lifesciences Limited, Melinta Therapeutics Inc., Asieris Pharmaceuticals, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the genitourinary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genitourinary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genitourinary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the genitourinary drugs market by increasing prices for antibiotics, hormonal therapies, and urological drug ingredients. UTI, BPH, and hormonal therapy segments are most affected, particularly in North America and Europe due to reliance on imported APIs. Hospital and retail pharmacies face cost increases. However, tariffs are encouraging local pharmaceutical manufacturing and generic drug production.

The genitourinary drugs market research report is one of a series of new reports that provides genitourinary drugs market statistics, including genitourinary drugs industry global market size, regional shares, competitors with a genitourinary drugs market share, detailed genitourinary drugs market segments, market trends and opportunities, and any further data you may need to thrive in the genitourinary drugs industry. This genitourinary drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genitourinary drugs are medications designed to treat disorders of the urinary and reproductive systems, including the kidneys, bladder, urethra, and genital organs. They are used to manage infections, alleviate urinary symptoms, treat erectile dysfunction, control overactive bladder, and regulate hormonal functions, ultimately improving genitourinary health and patient quality of life.

The main types of genitourinary drugs include urologicals, hormonal therapies, gynecological drugs, anti-infectives, and others. Urologicals are medications specifically targeting urinary tract and male reproductive disorders. These drugs are administered through oral, parenteral, or topical routes and are applied to treat conditions such as urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), prostate cancer, overactive bladder, and bladder cancer. Distribution occurs via hospital pharmacies, retail and drugstore pharmacies, and online pharmacies, serving end users including hospitals, clinics, specialty centers, and homecare settings.

The genitourinary drugs market consists of sales of urinary acidifiers and alkalinizers, desmopressin, diuretics, urinary antispasmodics, anti-infectives, and hormone replacement therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.